Effect of MTHFR polymorphisms on hyperhomocysteinemia in levodopa-treated Parkinsonian patients

NeuroMolecular Medicine

Volumn 9, Issue 3, 2007, Pages 249-254

  Caccamo, D ^a   Gorgone, G ^a   Curro M ^a   Parisi, G ^a   Di Iorio, W ^b,c   Menichetti, C ^b,c   Belcastro, V ^d   Parnetti, L ^b,c   Rossi, A ^b,c   Pisani, F ^d   Ientile, R ^a   Calabresi, P ^b,c  

^a UNIVERSITY OF MESSINA   (Italy)

^b UNIVERSITY OF PERUGIA   (Italy)

^c IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^d UNIVERSITY OF MESSINA   (Italy)

Author keywords

Folate; Homocysteine; Levodopa; MTHFR genotypes; Parkinson's disease

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE; LEVODOPA;

ADULT; AGED; AMINO ACID BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME POLYMORPHISM; FEMALE; GENOTYPE; HUMAN; HYPERHOMOCYSTEINEMIA; MALE; PARKINSON DISEASE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR;

AGED; ANTIPARKINSON AGENTS; FEMALE; FOLIC ACID; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; LEVODOPA; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; PARKINSON DISEASE; POLYMORPHISM, GENETIC; VITAMIN B 12;

PARKINSONIA;

EID: 36248991812     PISSN: 15351084     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12017-007-8006-x     Document Type: Article

References (33)

1. Brattstrom, L. (2001). Plasma homocysteine and MTHFR C677T genotype in levodopa-treated patients with PD. Neurology, 56, 281.
2. Bialecka, M, Drozdzik, M, Klodowska-Duda, G, Honczarenko, K, Gawronska-Szklarz, B, Opala, G, & Stankiewicz, J. (2004). The effect of monoamine oxidase B (MAOB) and catechol-O-methyltransferase (COMT) polymorphisms on levodopa therapy in patients with sporadic Parkinson's disease. Acta Neurologica Scandinavica, 110(4), 260-266.
3. Caccamo, D., Condello, S., Gorgone, G., Crisafulli, G., Belcastro, V., Gennaro, S., Striano, P., Pisani, F., & Ientile, R. (2004). Screening for C677T and A1298C MTHFR polymorphisms in patients with epilepsy and risk of hyperhomocysteinemia. Neuromol. Med., 6, 117-126.
4. Contin, M, Martinelli, P, Mochi, M, Riva, R, Albani, F, & Baruzzi, A. (2005). Genetic polymorphism of catechol-O-methyltransferase and levodopa pharmacokinetic-pharmacodynamic pattern in patients with Parkinson's disease. Movement Disorders, 20(6), 734-739.
5. de Lau, L. M., Koudstaal, P. J., van Meurs, J. B., Uitterlinden, A. G., Hofman, A., & Breteler, M. M. (2005) Methylenetetrahydrofolate reductase C677T genotype and PD. Annals of Neurology, 57, 927-930.
6. Hankey, G. J., & Eikelboom, J. W. (1999) Homocysteine and vascular disease. Lancet, 354, 407-413.
7. Kluijtmans, L. A., van den Heuvel, L. P., Boers, G. H., Frosst, P., Stevens, E. M., van Oost, B. A., den Heijer, M., Trijbels, F. J., Rozen, R., & Blom, H. J. (1996). Molecular genetic analysis in mild hyperhomocysteinemia: A common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease. American Journal of Human Genetics, 58, 35-41.
8. Kruman, I. I., Kumaravel, T. S., Lohani, A., Pedersen, W. A., Cutler, R. G., Kruman, Y., Haughey, N., Lee, J., Evans, M., & Mattson, M. P. (2002). Folic acid deficiency and homocysteine impair DNA repair in hippocampal neurons and sensitize them to amyloid toxicity in experimental models of Alzheimer's disease. Journal of Neuroscience, 22, 1752-1762.
9. Kuhn, W., Hummel, T., Woitalla, D., & Muller, T. (2001). Plasma homocysteine and MTHFR C677T genotype in levodopa-treated patients with PD. Neurology, 56, 281.
10. Lamberti, P., Zoccolella, S., Armenise, E., Lamberti, S. V., Fraddosio, A., de Mari, M., Iliceto, G., & Livrea, P. (2005a). Hyperhomocysteinemia in L-dopa treated Parkinson's disease patients: Effect of cobalamin and folate administration. European Journal of Neurology, 12, 365-368.
11. Lamberti, P., Zoccolella, S., Iliceto, G., Armenise, E., Fraddosio, A., de Mari, M., & Livrea, P. (2005b). Effects of levodopa and COMT inhibitors on plasma homocysteine in Parkinson's disease patients. Movement Disorders, 20, 69-72.
12. 45Ca release in the rabbit hippocampus is mediated by both NMDA and group I metabotropic glutamate receptors: In vivo microdialysis study. Neurochemical Research, 28, 259-269.
13. Lee, E. S., Chen, H., Soliman, K. F., & Charlton, C. G. (2005). Effects of homocysteine on the dopaminergic system and behavior in rodents. Neurotoxicology, 26(3), 361-371.
14. Lipton, S. A., Kim, W. K., Choi, Y. B., Kumar, S., D'Emilia, D. M., Rayudu, P. V., Arnelle, D. R., & Stamler, J. S. (1997). Neurotoxicity associated with dual actions of homocysteine at the N-methyl-D- aspartate receptor. Proceedings of the National Academy of Sciences of the United States of America, 94(11), 5923-5928.
15. Malinow, M. R. (1999). Homocyst(e)ine, vitamins and genetic interactions in vascular disease. The Candian Journal of Cardiology, 15(Suppl B), 31B-34B.
16. Malinow, M. R., Nieto, F. J., Kruger, W. D., Duell, P. B., Hess, D. L., Gluckman, R. A., Block, P. C., Holzgang, C. R., Anderson, P. H., Seltzer, D., Upson, B., & Lin, Q. R. (1997). The effects of folic acid supplementation on plasma total homocysteine are modulated by multivitamin use and methylenetetrahydrofolate reductase genotypes. Arteriosclerosis, Thrombosis, and Vascular biology, 17, 1157-1162.
17. Mattson, M. P., & Shea, T. B. (2003). Folate and homocysteine metabolism in neural plasticity and neurodegenerative disorders. Trends in Neurosciences, 26, 137-146.
18. Miller, J. W., Selhub, J., Nadeau, M. R., Thomas, C. A., Feldman, R. G., & Wolf, P. A. (2003). Effect of L-dopa on plasma homocysteine in PD patients: relationship to B-vitamin status. Neurology, 60, 1125-1129.
19. Müller, T., & Kuhn, W. (2006). Tolcapone decreases plasma levels of S-adenosyl-L-homocysteine and homocysteine in treated Parkinson's disease patients. European Journal of Clinical pharmacology, 62, 447-450.
20. Müller, T., Werne, B., Fowler, B., & Kuhn, W. (1999). Nigral endothelial dysfunction, homocysteine, and Parkinson's disease. Lancet, 354, 126-127.
21. Müller, T, Woitalla, D, & Kuhn, W. (2003). Benefit of folic acid supplementation in Parkinsonian patients treated with levodopa. Journal of Neurology, Neurosurgery, and Psychiatry, 74, 549.
22. O'Suilleabhain, P. E., Teodoro Bottiglieri, T., Dewey, R. B. Jr., Shailja Sharma, S., & Diaz-Arrastia, R. (2004). Modest increase in plasma homocysteine follows levodopa initiation in Parkinson's disease. Movement Disorders, 19, 1403-1408.
23. Postuma, R. B., Espay, A. J., Zadikoff, C., Suchowersky, O., Martin, W. R., Lafontaine, A. L., Ranawaya, R., Camicioli, R., & Lang, A. E. (2006). Vitamins and entacapone in levodopa-induced hyperhomocysteinemia: A randomized controlled study. Neurology, 66, 1941-1943.
24. Religa, D., Czyzewski, K., Styczynska, M., Peplonska, B., Lokk, J., Chodakowska-Zebrowska, M., Stepien, K., Winblad, B., & Barcikowska, M. (2006). Hyperhomocysteinemia and methylenetetrahydrofolate reductase polymorphism in patients with Parkinson's disease. Neuroscience Letters, 404, 56-60.
25. Rogers, J. D., Sanchez-Saffon, A., Frol, A. B., & Diaz-Arrastia, R. (2003). Elevated plasma homocysteine levels in patients treated with levodopa: Association with vascular disease. Archives of Neurology, 60, 59-64.
26. Selhub, J., & Miller, J. W. (1992) The pathogenesis of homocysteinemia: Interruption of the coordinate regulation by S-adenosyl-methionine of the remethylation and transsulfuration of homocysteine. The American Journal of Clinical Nutrition, 55, 131-138.
27. Selhub, J. (2006). The many facets of hyperhomocysteinemia: Studies from the Framingham cohorts. Journal of Nutrition, 136, 1726-1730.
28. Todorovic, Z., Dzoljic, E., Novakovic, I., Mirkovic, D., Stojanovic, R., Nesic, Z., Krajinovic, M., Prostran, M., & Kostic, V. (2006). Homocysteine serum levels and MTHFR C677T genotype in patients with Parkinson's disease, with and without levodopa therapy. Journal of the Neurological Sciences, 248, 56-61.
29. Weisberg, I. S., Tran, P., Christensen, B., Sibani, S., & Rozen, R. (1998). A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Molecular Genetics and Metabolism, 64, 169-172.
30. Woitalla, D., Kuhn, W., & Muller, T. (2004). MTHFR C677T polymorphism, folic acid and hyperhomocysteinemia in levodopa treated patients with Parkinson's disease. Journal of Neural Transmission. Supplementum, 68, 15-20.
31. Wullner, U., Kolsh, H., & Linnebank, M. (2005). Methylenetetrahydrofolate reductase in Parkinson's disease. Annals of Neurology, 57, 927-930.
32. Yasui, K., Kowa, H., Nakaso, K., Takeshima, T., & Nakashima, K. (2000). Plasma homocysteine and MTHFR C677T genotype in levodopa-treated patients with PD. Neurology, 55, 437-440.
33. Zesiewicz, T. A., Wecker, L., Sullivan, K. L., Merlin, R. L., & Hauser, R. A. (2006). The controversy concerning plasma homocysteine in Parkinson disease patients treated with levodopa alone or with entacapone: effects of vitamin status. Clinical Neuropharmacology, 29, 106-111.